Golden
Senti Biosciences

Senti Biosciences

A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.

All edits

Edits on 14 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 2:09 pm
Edits made to:
Article (+11/-11 characters)

Article

Senti Biosciences is a synthetic biology company headquartered in South San Francisco, California and was founded in 2016 by Jim CollinsJim Collins, Philip Lee, Tim Lu, and Wilson Wong. 

Edits on 11 Sep 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 11 Sep 2019 7:35 pm
Edits made to:
Article (+14/-14 characters)

Article

On February 27, 2018 Senti Biosciences completed their series A funding round with $53 million in funding from New Enterprise Associates (lead investor), 8VC, Amgen VenturesAmgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital.

Golden AI
Golden AI edited on 11 Sep 2019 9:03 am
Edits made to:
Infobox (+1 properties)
Edits on 25 Jun 2019
Golden AI
Golden AI approved a suggestion from Golden's AI on 25 Jun 2019 4:07 am
Edits made to:
Infobox (+1 properties)
Edits on 1 May 2019
Sanghyeon Seo
Sanghyeon Seo approved a suggestion from Golden's AI on 1 May 2019 12:00 pm
Edits made to:
Article (+18/-18 characters)

Article

Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of Synlogic, Tango Therapeutics, Sample6, Eligo BiomX and Engine BiosciencesEngine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo. 

Edits on 30 Apr 2019
Phillip Johnston
Phillip Johnston approved a suggestion from Golden's AI on 30 Apr 2019 10:45 pm
Edits made to:
Article (+18/-18 characters)

Article

Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of Synlogic, Tango TherapeuticsTango Therapeutics, Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo. 

Mark Cundy
Mark Cundy approved a suggestion from Golden's AI on 30 Apr 2019 9:32 pm
Edits made to:
Article (+11/-11 characters)

Article

On February 27, 2018 Senti Biosciences completed their series A funding round with $53 million in funding from New Enterprise Associates (lead investor), 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega FundsOmega Funds, Goodman Capital, and LifeForce Capital.

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:53 am
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 2 Apr 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 2 Apr 2019 8:15 pm
Edits made to:
Article (+31/-31 characters)

Article

Senti Biosciences is a synthetic biology company headquartered in South San Francisco, CaliforniaSouth San Francisco, California and was founded in 2016 by Jim Collins, Philip Lee, Tim Lu, and Wilson Wong. 

Edits on 30 Mar 2019
Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 10:17 pm
Edits made to:
Infobox (+7 properties)
Article (+489 characters)
Related Topics (+2 topics)

Article

Senti Biosciences is a synthetic biology company headquartered in South San Francisco, California and was founded in 2016 by Jim Collins, Philip Lee, Tim Lu, and Wilson Wong. 



...

The company aims to make gene therapies more adaptive and able to respond dynamically to disease conditions. Senti’s technology platform aims to allow cellular therapies to be controlled after they are administered and respond in a multifactorial way depending on the disease state and desired outcome.

...

Funding

Series A

On February 27, 2018 Senti Biosciences completed their series A funding round with $53 million in funding from New Enterprise Associates (lead investor), 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital.

Infobox

Related Topics

Edits on 21 Mar 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 21 Mar 2019 12:21 am
Edits made to:
Article (+8/-8 characters)

Article

Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of SynlogicSynlogic, Tango Therapeutics, Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo. 

Edits on 19 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:47 pm
Edits made to:
Article (+17/-17 characters)

Article

Senti has a proprietary synthetic biologysynthetic biology platform for development of therapeutics. The company uses genetic circuits to program cell therapies so that they have localized action, sensors, dynamic responses and safety control. Senti has a design platform for synthetic gene circuits for fast design, building and testing of therapeutic circuits. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:45 pm
Edits made to:
Article (+6/-6 characters)

Article

Usually CARs are expressed as full-length fusion proteins composed of ligand-binding, transmembrane and signaling domains. SUPRA CAR systems have two components, a zipCARzipCAR and a zipFv fragment. The zipCAR has intracellular signaling domains connected by a transmembrane segment to an extracellular domain that has a protein structural motif called a leucine zipper. The zipFv has a ligand-binding scFv domain fused to a second leucine zipper. Engineered T-cells that express zipCARs are not functional until zipFv proteins are added that have matching leucine zippers. Functional CAR reconstitution can be inhibited by adding a competing zipFv that dimerizes with the first zipFv. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:41 pm
Edits made to:
Article (+16/-16 characters)

Article

Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer ScienceComputer Science and co-founder of Synlogic, Tango Therapeutics, Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo. 

Edits on 18 Mar 2019
Carla Faraguna"Approved suggestion from source: https://www.sentibio.com/"
Carla Faraguna approved a suggestion from Golden's AI on 18 Mar 2019 11:06 pm
Edits made to:
Infobox (+1 properties)
Edits on 18 Mar 2019
Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 12:35 am
Edits made to:
Article (+1330 characters)

Article

Usually CARs are expressed as full-length fusion proteins composed of ligand-binding, transmembrane and signaling domains. SUPRA CAR systems have two components, a zipCAR and a zipFv fragment. The zipCAR has intracellular signaling domains connected by a transmembrane segment to an extracellular domain that has a protein structural motif called a leucine zipper. The zipFv has a ligand-binding scFv domain fused to a second leucine zipper. Engineered T-cells that express zipCARs are not functional until zipFv proteins are added that have matching leucine zippers. Functional CAR reconstitution can be inhibited by adding a competing zipFv that dimerizes with the first zipFv. 



The system makes the cellular therapy capable of Boolean-logic signal integration such as OR-gate and A-and-not-B signal by adding different zipFv sequences. Antigen specificity and binding affinity of the CAR is determined by externally added zipFv sequences. In principle the system could allow a generic or off-the-shelf zipCAR-T cell product, where the antigen specificity can be altered during the treatment course. 



In their 2018 Cell publication about the SUPRA CAR system, authored by Cho, Collins and Wong, human transcription factors were used to derive leucine zipper domains for SUPRA CAR-T cell control of tumor growth in mouse models. 



Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Mar 2019 9:12 pm
Edits made to:
Article (+7/-7 characters)

Article

Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of Synlogic, Tango Therapeutics, Sample6Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo. 

Meredith Hanel
Meredith Hanel edited on 17 Mar 2019 9:02 pm
Edits made to:
Infobox (+5 properties)
Article (+985/-110 characters)
People (+6 rows) (+12 cells) (+259 characters)
Categories (+2 topics)
Related Topics (+2 topics)
Topic thumbnail

Senti Biosciences

A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.

Article

The company aims to make gene therapies more adaptive and able to respond dynamically to disease conditions. OneSenti’s oftechnology theirplatform geneaims to allow cellular therapies to be controlled after they are administered and respond in development is botha universalmultifactorial andway programmable,depending calledon the SUPRAdisease CAR-Tstate systemand desired outcome.

...

Senti is developing T cell immunotherapies that target cancer using chimeric antigen receptors (CARs). One of their therapies in development is called the "split universal, and programmable" (SUPRA) CAR-T system. The SUPRA CAR system allows T cells to switch targets without re-engineering them and T cell activation can be fine tuned as well as sense and logically respond to multiple antigens. These characteristics may help these CAR-T cells to respond to relapse, mitigate over-activation and make the therapy more specific. 



Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of Synlogic, Tango Therapeutics, Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as CSOChief Scientific Officer. SantiSenti’s chiefChief financialFinancial officerOfficer Curt Herberts also comes from Sangamo. 

People

Name
Role
Related Golden topics

Gary Lee, Ph.D.​

Chief Scientific Officer



Philip Lee, Ph.D.

Co-Founder, COO



Curt Herberts, M.B.S.

Chief Financial Officer and Chief Business Officer



Jim Collins, Ph.D.

Scientific Co-Founder



Tim Lu, M.D., Ph.D.

Co-Founder, CEO



Wilson Wong, Ph.D.

Scientific Co-Founder



Infobox

Categories

Related Topics

Meredith Hanel
Meredith Hanel edited on 17 Mar 2019 7:54 pm
Edits made to:
Description (+245 characters)
Article (+728 characters)
Topic thumbnail

Senti Biosciences

A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.

Article

Senti has a proprietary synthetic biology platform for development of therapeutics. The company uses genetic circuits to program cell therapies so that they have localized action, sensors, dynamic responses and safety control. Senti has a design platform for synthetic gene circuits for fast design, building and testing of therapeutic circuits. 



The company aims to make gene therapies more adaptive and able to respond dynamically to disease conditions. One of their gene therapies in development is both universal and programmable, called the SUPRA CAR-T system. 

...

In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as CSO. Santi’s chief financial officer Curt Herberts also comes from Sangamo. 

Edits on 7 Mar 2019
Golden AI
Golden AI edited on 7 Mar 2019 10:14 pm
Edits made to:
Infobox (+1 properties)

Infobox